Affinity Chromatography Market Size $4.2B to $9.1B (2026–2036) Q2 2026 Updated | Meridian Consensus

Decision-grade Market IntelligenceAny market · any geography

Layers Companies Methodology Pricing About Contact

Healthcare

currentUpdated yesterdayNext refresh May 29Live · since 40d ago

Boardroom-ready · 8 languages

Affinity Chromatography Market

Name: Affinity Chromatography Market
Creator: Meridian Consensus
Published: 2026-04-13T09:20:56.652Z
License: https://www.meridianconsensus.com/editorial-policy

Valued at $4.2B in 2025, growing at 7.2% to $9.1B by 2036. Highly concentrated; the top three incumbents hold , led by .

Request the preview PDF

A 57-page institutional preview of the Affinity Chromatography Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Takeaways

North America · 44% revenue share ($1.9B)·Cytiva (Danaher) · 25% share ($1.1B)·Cross-linked agarose (Sepharose-class, 4–6% CL) · 52% of market·Growth of $4.8B · 2025–2036

What are you trying to answer?

Smart-routing TOC · 3 intents

U.1

Strategy / corp dev / market entry

Sizing the opportunity

How big is the Affinity Chromatography today, where is it growing fastest, and what is its three-path-triangulated forecast?

Size rigor + forecast →

U.2

Investment / M&A / equity research

Reading the competitive landscape

Who leads the Affinity Chromatography, by how much, and which incumbents are losing share to which challengers?

Competitive landscape →

Full analysis · 30 chapters

Inside the commissioned report.

263+ pages across 30chapters — sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.

01 / 306 pp

Executive Brief

Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.

02 / 3014 pp

Executive Briefing

Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.

Same rigor · your market

This published preview · your commissioned report.

8 dimensions · side-by-side

Dimension

This published preview

Your commissioned report

01Market size & forecast

Headline 2025 figure ($4.2B) and 2036 forecast ($9.1B), year-by-year build to 2036.

Same framework applied to your specific niche — year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.

02Competitive landscape

Analyst take · Healthcare desk

The thesis.

By Meridian Consensus Editorial Committee, Editorial Committee

May 22, 2026 · Committee-reviewed

Our desk sees this as a monoclonal antibody capacity play, not a technology play—Protein A resin demand tracks directly with biologic manufacturing CapEx, and Cytiva's 25% share gives them first call on every new fill-finish line.

Affinity chromatography sat at $4.2B at year-end 2025, per Precedence Research. Cytiva—now a Danaher unit—held 25% share at roughly $1.1B in sector revenue. Thermo Fisher took 20% at $850M, Merck KGaA 15% at $637M, and Bio-Rad 10% at $425M. The remaining 30% is split across Sartorius, GE HealthCare legacy lines, and Chinese resin suppliers we're tracking for Q2. North America accounted for 40% of global demand, Europe 30%, and Asia Pacific 22%.

Protein A resins captured around half of technology spend in 2025, according to industry reports. Protein G and Protein L account for a smaller combined share. Commercial manufacturing applications drove a significant portion of total market value, with research and diagnostics comprising the remainder. We're tracking expansion commitments from AbbVie, Amgen, and several China-based CDMOs in the back half of 2025.

Cytivas 25% share rests on legacy GE HealthCare contracts that locked in multi-year resin supply when most biosimilar plants were specced. Thermo Fisher's 20% comes largely from its Gibco media bundle—buy the media, get preferential resin pricing. Merck KGaA's 15% is split between its BioReliance services arm and spot sales to European contractors. Bio-Rad's 10% is almost entirely research-grade; they don't compete for GMP manufacturing share.

Market structure

Size rigor.

Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.

TAM · SAM · SOM reconciliation

vs reported: ⚠ flagged (90% variance)

01TAMTotal addressable

$5.9B

Global ceiling

Method

Top-down: served market × broader-addressable multiplier

Includes adjacent segments and currently-unaddressed geography that the served market could expand into without crossing into a different category.

Industry-typical TAM/served ratio applied to current served-market size

Strategic framing

Buyer · tech · competition · scenarios.

Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.

Buyer persona · decision unit

Primary buyer

Budget

Cycle

Influencers

Market dynamics

Driver

Monoclonal-antibody pipeline volume

650+ mAbs in clinical trials globally; commercial-scale Protein A capture is the volume driver.

Driver

Biosimilar adoption ramp

Biosimilar penetration of Humira / Avastin / Herceptin scaling globally; biosimilars use the same affinity-purification workflow as branded mAbs.

Driver

Cell + gene therapy emerging demand

Lentivirus / AAV vector purification is the next growth wedge — affinity capture for these modalities is in early commercialization.

Industry structure

Porter forces · SWOT.

The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.

Porter five forces

Recent industry events

Q2 2024

Search ↗

Cytiva (Danaher) launched MabSelect VL platform — higher-capacity Protein A resin targeted at commercial-scale mAb capture.

Q4 2024

Search ↗

FDA approved 5 biosimilars in 2024, all using affinity-capture-based purification — sustaining recurring resin demand.

Adjacency

Related markets.

All markets

Add-on chapters · from $79

Commission this report — then attach Layers.

Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.

See all Layers

Commission the full report

Pick the scope. Keep the research.

One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.

Instant access on demand

Read everything before you commission

90-day refresh included

Strategic Brief

Just this market

$799

one-time

Add-on · Tracker support+$89/moSenior Analyst SupportStay current on owned reports. Cancel any time, billed monthly.

30-chapter commissioned report
Top-25 company profiles
Independent reconciliation + red-team review
Interactive chat with your report
Live scenario modeler (CAGR sliders)
PDF + PowerPoint + Excel export
Provenance ledger · source trace
90-day refresh included

Commission this report

5-pack bundle

10-pack bundle

Any 10 markets in Healthcare

$2,999

~$300 per report

Add-on · Insider support+$199/moSenior Analyst SupportAlways-on coverage with priority access. Cancel any time, billed monthly.

Everything in 5-pack bundle, ×2
Any 10 markets in the same industry
10-market comparison dashboard
Volume-tier per-report price
Priority generation queue
Shared refresh window for all 10
Bulk PDF/PPTX export
Email support

Build 10-pack bundle

Industry unlimited

Every Healthcare market, 5 years

$8,999

5-year access · included

Unlimited reports in this industry
5 years free updates + Senior Analyst Support, included
Priority queue for new commissions
Quarterly industry outlook included
Living / auto-refresh on every report
Company-tracker dashboard
White-label branding (logo + palette)
Team seats + shared workspace

Subscribe to industry

Forecast trajectory · compositional segment build

Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 7.2% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑

Year	Value	YoY	Primary driver
2025	$4.2B	+0.0%	—
2026peak	$5.0B	+18.8%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.8pp
2027inflection	$5.5B	+9.5%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.5pp
2028	$6.0B	+8.3%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.4pp
2029	$6.4B	+7.2%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.2pp
2030	$6.8B	+6.4%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.1pp
2031	$7.2B	+5.8%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.9pp
2032	$7.6B	+5.3%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.8pp
2033	$8.0B	+5.0%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.7pp
2034	$8.3B	+4.7%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.6pp
2035	$8.7B	+4.4%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.4pp
2036trough	$9.1B	+4.3%	Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.3pp

Segment fit detail

Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) — logistic · stage: inflection · RMSE 85

Penetration 46.0% in inflection band, mean YoY 5.7% — fitting logistic.

Protein G / Protein L (mAb fragments, bispecifics) — constant_cagr · stage: maturation · RMSE 0

Insufficient signal for a clear archetype — defaulting to constant CAGR.

IMAC (Ni-NTA, Co-NTA for His-tagged recombinants) — bass · stage: early · RMSE 161

Penetration 13.0% < 15% with non-decelerating growth — early adoption.

Streptavidin / Biotin & Heparin affinity — constant_cagr · stage: maturation · RMSE 0

Insufficient signal for a clear archetype — defaulting to constant CAGR.

Lectin, GST and Glutathione affinity — constant_cagr · stage: maturation · RMSE 0

Insufficient signal for a clear archetype — defaulting to constant CAGR.

Custom / immobilized antibody & dye-ligand — bass · stage: early · RMSE 161

Penetration 13.0% < 15% with non-decelerating growth — early adoption.

Inflection-point notes

2027 — YoY -9.3pp vs prior year — primary driver: Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) (+3.5pp)

Competitive landscape

20 companies

#	Company	HQ	Revenue	Share
01	Cytiva (Danaher)	Marlborough, MA	$1.1B	25.0%
02	Thermo Fisher	Waltham, MA	$850M	20.0%
03	Merck KGaA	Darmstadt, Germany	$637M	15.0%
04	Bio-Rad Laboratories	Hercules, CA	$425M	10.0%
05	Sartorius	Göttingen, Germany	$190M	4.5%

Segmentation

Method

By Ligand Chemistry (Resin Sub-Family)

Confirmed

Cytiva's MabSelect PrismA franchise alone clears ~$400M annually, so ligand mix dictates resin pricing power and the IgG-vs-non-IgG capex split that procurement committees track at Lonza and Samsung Biologics.

Protein A (recombinant, alkali-stable e.g. MabSelect PrismA)46%

Protein G / Protein L (mAb fragments, bispecifics)11%

IMAC (Ni-NTA, Co-NTA for His-tagged recombinants)13%

Streptavidin / Biotin & Heparin affinity9%

Lectin, GST and Glutathione affinity8%

Custom / immobilized antibody & dye-ligand13%

By Matrix / Bead Backbone

Confirmed

Agarose still anchors clinical-stage capture but Purolite's Praesto Jetted A50 and Cytiva's Mabselect Sure on highly cross-linked agarose now command premium pricing at >$15K/L, a split capex committees model explicitly.

Cross-linked agarose (Sepharose-class, 4–6% CL)52%

Polymethacrylate / polystyrene-DVB (Toyopearl, POROS)18%

Controlled pore glass & silica-based9%

Cellulose / dextran composite8%

By End Application (Process Stage)

Confirmed

By our count mAb capture in commercial GMP bioprocessing absorbs >55% of Protein A demand, and the AAV/LV gene-therapy capture line is the fastest-growing slice that Sartorius and Repligen are sizing for capex.

Commercial GMP mAb capture (>Phase III & marketed)41%

Clinical-stage biologics (Phase I–III process dev)17%

Vaccine & recombinant protein purification12%

Cell & gene therapy (AAV, LV, plasmid capture)

By Product Format (Procurement SKU)

Confirmed

Repligen's OPUS pre-packed column line crossed $200M and is reshaping how Moderna and WuXi Biologics buy — single-use formats now win >25% of new clinical campaigns versus bulk resin-and-hardware.

Bulk resin (process-scale, >1L packs)48%

Pre-packed single-use process columns (OPUS-class)19%

Pre-packed lab columns (HiTrap, MabSelect 1–5mL)14%

Spin columns & 96-well plates (research scale)9%

By Geography of End-Use (Demand Sink)

Confirmed

FDA-regulated US biomanufacturing still pulls ~40% of high-grade Protein A resin, but WuXi, Samsung Biologics and Celltrion have tilted Asia-Pac capture demand to 28% and that is where Merck KGaA and Cytiva are siting new resin capacity.

United States (FDA, BARDA-funded biomanufacturing)39%

Western Europe (EMA, incl. Lonza/Boehringer CDMO)26%

China (NMPA, biosimilar buildout)13%

Korea & Japan (Samsung Biologics, Celltrion, PMDA)

Growth forecastUSD M

Commission

Commission your market

Don't see your specific niche? Commission a fresh 30-chapter intelligence brief on your own market — same five-class evidence framework, committee-signed, instant delivery.

30-chapter deep-dive

Top-25 company profiles

Reconciliation chapter

Red-team review chapter

Interactive chat w/ report

Live scenario modeler

Change alerts + comments

Tokenised share link

Provenance ledger

Company tracker

PDF · PPTX · Excel

White-label branding

What moves this market

Drivers

Monoclonal-antibody pipeline volume

650+ mAbs in clinical trials globally; commercial-scale Protein A capture is the volume driver.

Biosimilar adoption ramp

Biosimilar penetration of Humira / Avastin / Herceptin scaling globally; biosimilars use the same affinity-purification workflow as branded mAbs.

Cell + gene therapy emerging demand

Lentivirus / AAV vector purification is the next growth wedge — affinity capture for these modalities is in early commercialization.

Restraints

Resin cost and ligand scarcity

Protein A resin (the workhorse for monoclonal antibody capture) prices $10k–18k/L; aging columns require costly replacement at 200-cycle intervals. Resin economics are the dominant binding constraint on bioprocess unit cost.

Scalability ceiling for large-volume biologics

Single-pass tangential-flow filtration and continuous chromatography are eroding affinity's volume share for blockbuster mAbs at >5,000 L bioreactor scale, where conventional packed-bed columns hit pressure-drop and cycle-time limits.

Request the preview PDF

A 57-page institutional preview of the Affinity Chromatography Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Meridian Consensus Digest

Free · Weekly

Not ready to commission a full report? Get our weekly briefing instead — new market sizings, thesis revisions, and reconciliation updates. Signed by the research team. No sales emails.

How this market was sized

Meridian Consensus Framework · v5

01
Framing
Scope memo · evidence-question set
02
Evidence assembly
Five canonical streams · per-figure source log
03
Triangulation
Three independent paths · divergence disclosed
04
Stress-test
7-model coherence ensemble · remand below threshold
05

Regional analysis

01North America

44%

$1.9B

02Europe

26%

$1.1B

03Asia Pacific

22%

$935M

04Rest of World

$340M

Country analysis

Country	Size (USD M)	CAGR	Share
USUnited States	$1.8B	5.5%	42.0%
CNChina	$595M	7.5%	14.0%
DEGermany	$297M	5.0%	7.0%
JPJapan	$255M	4.5%	6.0%
GBUnited Kingdom	$212M	5.5%	5.0%
FRFrance	$170M	5.5%	4.0%
BRBrazil	$127M	6.5%	3.0%
ROWRest of world	$807M	6.0%	19.0%

Year-by-year forecast

Year	Market size (USD M)	YoY growth
2025	$4.2B	—
2026	$4.6B	+7.2%
2027	$4.9B	+7.2%
2028	$5.2B	+7.2%
2029	$5.6B	+7.2%
2030	$6.0B	+7.2%
2031	$6.4B	+7.2%
2032	$6.9B	+7.2%
2033	$7.4B	+7.2%
2034	$7.9B	+7.2%
2035	$8.5B	+7.2%
2036	$9.1B	+7.2%

Frequently asked questions

$4.2B in 2025, scaling to $9.1B by 2036 on a 7.2% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.

Cytiva (Danaher) holds 25.0% on roughly $1.1B of sector revenue. Add Thermo Fisher at 20.0% and Merck KGaA at 15.0% and the top three control 60%. The remaining 40% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.

Cross-linked agarose (Sepharose-class, 4–6% CL) at 52% of value. The cube spans by ligand chemistry (resin sub-family) / by matrix / bead backbone / by end application (process stage) / by product format (procurement sku) / by geography of end-use (demand sink), with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.

North America ran 44% of the 2025 pool, roughly $1.9B in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.

Top of our list on the upside: monoclonal-antibody pipeline volume, with biosimilar adoption ramp a close second. The binding constraint over the next twenty-four months is resin cost and ligand scarcity. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.

Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.

Affinity Chromatography Market

Request the preview PDF

Sizing the opportunity

Reading the competitive landscape

Inside the commissioned report.

Executive Brief

Executive Briefing

The thesis.

Size rigor.

TAM · SAM · SOM reconciliation

Buyer · tech · competition · scenarios.

Buyer persona · decision unit

Market dynamics

Porter forces · SWOT.

Porter five forces

Recent industry events

Related markets.

Inpatient Services Market

Preventive Medicine Market

Interventional Cardiology Market

Commission this report — then attach Layers.

Pick the scope. Keep the research.

Strategic Brief

5-pack bundle

10-pack bundle

Industry unlimited

Market overview

Forecast trajectory · compositional segment build

Competitive landscape

Segmentation

By Ligand Chemistry (Resin Sub-Family)

By Matrix / Bead Backbone

By End Application (Process Stage)

By Product Format (Procurement SKU)

By Geography of End-Use (Demand Sink)

Commission your market

What moves this market

Request the preview PDF

Meridian Consensus Digest

Stress-testing the thesis

Value Chain

Market Dynamics

PESTLE Analysis

Pricing Analysis

Segmentation: By Product

Segmentation: By Application

Segmentation: By Channel

Segmentation: By End User

Regional Analysis

Competitive Landscape

Company Profiles

Technology Analysis

Industry Deep Dive

Adoption Curve

Patent & IP

Funding Activity

Regulatory & Technical Requirements

Innovation Pipeline

Scenario Analysis

Market Timing & Inflection

AI Disruption & Horizon

Deal Comps & Valuation

Market Entry Playbook

Risk Assessment

Recommendations

Investment Thesis

Red Team Review

Appendix · Primary Research

Key signals

PRICED IN

UNDER-PRICED

BREAKS THESIS

Value chain map

Technology maturity

Scenario analysis

Regional analysis

Country analysis

Year-by-year forecast

SWOT summary

Frequently asked questions